[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009013677A - 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators. - Google Patents

4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators.

Info

Publication number
MX2009013677A
MX2009013677A MX2009013677A MX2009013677A MX2009013677A MX 2009013677 A MX2009013677 A MX 2009013677A MX 2009013677 A MX2009013677 A MX 2009013677A MX 2009013677 A MX2009013677 A MX 2009013677A MX 2009013677 A MX2009013677 A MX 2009013677A
Authority
MX
Mexico
Prior art keywords
cannabinoid
dihydro
receptor modulators
compounds
methods
Prior art date
Application number
MX2009013677A
Other languages
Spanish (es)
Inventor
Josephus H M Lange
Bernard J Van Vliet
Mahmut Yildirim
Hendrik C Wals
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Priority claimed from PCT/EP2008/057367 external-priority patent/WO2008152086A2/en
Publication of MX2009013677A publication Critical patent/MX2009013677A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates to 4,5-dihydro-(1 H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor modulators, to pharmaceutical compositions containing these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CB1 receptors are involved, or that can be treated via manipulation of those receptors. The compounds have formula (I) wherein the symbols have the meanings given in the specification.
MX2009013677A 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators. MX2009013677A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110327 2007-06-15
PCT/EP2008/057367 WO2008152086A2 (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators

Publications (1)

Publication Number Publication Date
MX2009013677A true MX2009013677A (en) 2010-04-07

Family

ID=38674907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013677A MX2009013677A (en) 2007-06-15 2008-06-12 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators.

Country Status (5)

Country Link
CN (1) CN101939300A (en)
AR (1) AR066961A1 (en)
BR (1) BRPI0813367A2 (en)
MX (1) MX2009013677A (en)
TW (1) TW200916442A (en)

Also Published As

Publication number Publication date
BRPI0813367A2 (en) 2016-10-25
CN101939300A (en) 2011-01-05
AR066961A1 (en) 2009-09-23
TW200916442A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
NO20083193L (en) 4,5-Dihydro- (1H) -pyrazole derivatives as cannabinoid CB1 receptor modulators
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2008012400A (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity.
HK1092152A1 (en) Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
UA99524C2 (en) Triazole derivatives useful for the treatment of diseases
EA018629B8 (en) Phenyl and benzodioxinyl substituted indazoles derivatives
MX2009006540A (en) Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders.
WO2009106980A3 (en) Indazole derivatives
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2012002583A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators.
MX2009003981A (en) Calcium receptor modulating agents.
MX2010009462A (en) Indazole derivatives.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2011006132A (en) Fused imidazole carboxamides as trpv3 modulators.
GB0611907D0 (en) Compounds
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW200730500A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
WO2009037244A3 (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
MX2010003059A (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists.
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
ATE407119T1 (en) PYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF THE CB2 RECEPTOR